Volume 100, Issue 1 pp. 33-39

Illegitimate transcription: its use for studying genetic abnormalities in lymphoblastoid cells from patients with Glanzmann thrombasthenia

Claude Negrier

Claude Negrier

Centre de Traitement de l'Hémophilie, Hôpital Edouard Herriot, Lyon,

Laboratoire d'Hémobiologie, INSERM U331, Faculté RTH Laennec, Lyon, France

Search for more papers by this author
Christine Vinciguerra

Christine Vinciguerra

Centre de Traitement de l'Hémophilie, Hôpital Edouard Herriot, Lyon,

Laboratoire d'Hémobiologie, INSERM U331, Faculté RTH Laennec, Lyon, France

Search for more papers by this author
Olivier Attali

Olivier Attali

Centre de Traitement de l'Hémophilie, Hôpital Edouard Herriot, Lyon,

Laboratoire d'Hémobiologie, INSERM U331, Faculté RTH Laennec, Lyon, France

Search for more papers by this author
Christine Grenier

Christine Grenier

Laboratoire d'Hémobiologie, INSERM U331, Faculté RTH Laennec, Lyon, France

Search for more papers by this author
Marie Estelle Larcher

Marie Estelle Larcher

Laboratoire d'Hémobiologie, INSERM U331, Faculté RTH Laennec, Lyon, France

Search for more papers by this author
Marc Dechavanne

Marc Dechavanne

Centre de Traitement de l'Hémophilie, Hôpital Edouard Herriot, Lyon,

Laboratoire d'Hémobiologie, INSERM U331, Faculté RTH Laennec, Lyon, France

Search for more papers by this author
First published: 25 December 2001
Citations: 9
Dr Claude Negrier Centre de Traitement de l'Hémophilie, Hôpital Edouard Herriot, Pavillon E, Place d'Arsonval, 69003 Lyon, France.

Abstract

Glanzmann thrombasthenia is the most common inherited disorder of platelets that may induce severe bleeding complications. Molecular biology techniques have offered the possibility to assess the basis of this chronic haemorrhagic disease at the molecular level. However, the accessibility of mRNA in platelets is limited by the availability of the patient's blood samples and the relatively weak amount of this material in these cells. Taking advantage of the genetic phenomenon of illegitimate transcription, we have demonstrated that glycoprotein IIb and glycoprotein IIIa mRNA could be detected in lymphoblastoid cell lines issued from normal EBV-transformed lymphoblasts. We further analysed the sequences of the two glycoprotein transcripts in lymphoblastoid cell lines from two previously characterized patients presenting with Glanzmann thrombasthenia. The results showed that illegitimate transcripts presented similar molecular abnormalities to those found in platelets. These data demonstrated that the nucleotide sequences of illegitimate transcripts were identical to tissue-specific mRNA found in platelets. We applied this methodology to screen for the genetic defect in a new thrombasthenic patient, and found a homozygous nonsense mutation GCA → TGA converting Arg8 to stop in the glycoprotein IIIa gene. This immortalized source of genetic material is therefore particularly useful for molecular genetic studies in inherited platelet disorders, avoiding repetitive and large blood samplings in frequently anaemic patients.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.